NCT06139419 2025-11-17
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
Sun Yat-sen University
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT06607926 2024-09-23
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
Xuanwu Hospital, Beijing
Phase NA Not yet recruiting
NCT06598839 2024-09-19
Immuno-effect of Tα1 for Stage I NSCLC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Recruiting
NCT03659578 2022-01-03
Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Completed
NCT02542137 2019-03-21
Abscopal Effect for Metastatic Small Cell Lung Cancer
Zhejiang Provincial People's Hospital
Phase 2 Withdrawn
NCT02787447 2016-11-25
Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy
First People's Hospital of Hangzhou
Phase 2 Unknown
NCT02906150 2016-09-19
Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type
SciClone Pharmaceuticals
Phase 2 Unknown
NCT02906163 2016-09-19
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
SciClone Pharmaceuticals
Phase 1/2 Unknown